Inhibitory Effect on 3H-Diazepam Binding and Potentiating Action on GABA of Ethyl Loflazepate, a New Minor Tranquilizer

Total Page:16

File Type:pdf, Size:1020Kb

Inhibitory Effect on 3H-Diazepam Binding and Potentiating Action on GABA of Ethyl Loflazepate, a New Minor Tranquilizer Inhibitory Effect on 3H-Diazepam Binding and Potentiating Action on GABA of Ethyl Loflazepate, a New Minor Tranquilizer Yutaka SAKAI and Misako NAMIMA Department of Pharmacology, National Defense Medical College, Tokorozawa, Saitama 359, Japan Accepted January 7 1985 Abstract-A new benzodiazepine compound, ethyl loflazepate (ethyl -7-chloro 2,3-dihydro-5-(2-fluorophenyl)-2-oxo-1 H,1,4-benzodiazepine-3-carboxyl ate; CM 6912) was studied using in vitro experimental systems for its displacement activity on 3H-diazepam binding to the synaptosomal membrane fraction of rat cerebrum and potentiating action on GABA. CM6912 inhibited the specific binding of 3H diazepam by 25%, 75% and 90% at concentrations of 0.01 /tM, 0.1 /IM and 1 ,eM, respectively, while its metabolites CM691 3 and CM7116, at 0.1 ,uM, completely inhibited the binding. Concentrations for 50% inhibition (IC50) were 25 nM for CM691 2, 3.2 nM for CM691 3 and 1.4 nM for CM7116. These results suggest that the metabolite CM7116 is stronger than its parent compound in displacing the 3H-diazepam binding, and they also suggest that the long-lasting anti-anxietic action of CM691 2 might be due to the in vivo formation of CM7116. CM6912_, CM7116 and diazepam potentiated the suppressive action of GABA on spontaneous spikes of Purkinje cells in guinea pig cerebellar slices in a dose-dependent manner. Concentrations for 50% suppression (IC50) were 96.0 ,uM for GABA alone, 75.0 /iM for GABA plus diazepam (5 W), 78.9 /oM for GABA plus CM6912 (5 ,tM) and 60.8 ,uM for GABA plus CM71 16 (5 itM). These findings suggest that CM691 2 and CM7116 may potentiate the postsynaptic inhibitory action of GABA in a manner similar to and probably more strongly than diazepam. Since the first introduction of chlordiaze poxide by the Roche Co. in 1957, many benzodiazepine derivatives such as diazepam, nitrazepam, etc. have been commercialized in many countries. Some of these benzodiaze pines are clinically utilizied as anti-anxiety drugs (minor tranquilizers), and others are used as sleep inducers. Ethyl loflazepate (CM6912, ethyl -7-chloro-2,3-dihydro-5-(2 fluorophenyl)-2-oxo-1 H,1,4-benzodiazepine 3-carboxylate; Fig. 1) is one of the benzo diazepine derivatives synthesized first at the Clin-Midy Institute of the Sanofi Co. in France. As regards to the pharmacological ac tivities of this compound, some in vivo experiments with laboratory animals (1-3) and clinical studies (4, 5) including double blind tests have been carried out, and Fig. 1. Chemical structures of CM6912, CM691 3 CM6912 is now established as an anti and CM7116 and in vivo transformations. anxiety drug. diazepam was found to be suppressed by For the purpose of further clarifying the about 10% by this final concentration of pharmacological properties of CM6912, DMSO. The effect of a drug was expressed as quantitative studies utilizing in vitro experi the percentage of the binding in the presence mental systems were carried out in the of DMSO alone. present study. Particular interest was directed 2. Suppressive action of GABA on spon to the interaction with benzodiazepine taneous spike discharges of cerebellar receptors (6-11) and the potentiating Purkinje cells and the potentiation by actions on r-aminobutyric acid (GABA) of CM6912, CM7116 and diazepam of the not only CM6912_ but also its metabolites GABA action: The cerebellum isolated from a CM6913 and CM7116 (Fig. 1). guinea pig (300 g, male) was sagittally sectioned into 150 /'m thick slices using a Materials and Methods Vibratome. The cerebellar slices were placed 1. Displacement of 3H-diazepam binding: in an observation chamber which was kept The preparation of the cerebral membrane at 37°C with a circulating water jacket and fraction and the binding assay were carried continuously superfused (at a rate of 1 ml/ out according to the method of Squires and min) with Krebs-Ringer bicarbonate medium Braestrup (6). Briefly, the rat cerebrum was (pH 7.4) saturated with 95%/5%-O2/CO2 homogenized with 15 volumes of 0.32 M and kept at 37'C. Each drug solution was sucrose and centrifuged at 2,000xg for 5 min; applied by superfusion from a corresponding then the supernatant was centrifuged at reservoir. All solutions in the reservoirs were 30,000 x g for 10 min. The pellet was sus kept at 37'C and continuously bubbled with pended in 50 volumes of 50 mM Tris-HCI 95%/5%-O2/CO2. buffer (pH 7.4) and stored at -20°C. For Spontaneous spikes were extracellularly binding assays, 250 ,AI of the membrane recorded by placing a glass microelectrode suspension was incubated for 30 min at 4°C (filled with 2.5 M NaCl, 1-4 Mohm) close to with 10 iiI of 3H-diazepam solution (specific a Purkinje cell soma under a stereomicroscope activity=40 Ci/mmole, New England Nuclear, (X120). The number of spikes per each the final concentration of diazepam=1.65 nM) second was recorded and printed (12). and with 1.0 al of a drug solution. Then the Drugs tested were CM6912, CM7116 and incubation was terminated by adding 5 ml diazepam. These drugs were first dissolved of ice-cold 50 mM Tris-HCI buffer, and the in ethanol and diluted with warmed Krebs mixture was immediately filtered under Ringer bicarbonate medium (37'C) to give aspiration through a Whatman GF/C glass a final concentration of 5 W or 10 aM, the filter. The filter was washed with 5 ml of final ethanol concentration being 0.06% 50 mM Tris-HCI buffer (pH 7.4), dried and (13 mM). GABA was dissolved in Krebs placed in a scintillation vial for radioactivity Ringer bicarbonate medium to give final counting. Assays were carried out in duplicate. concentrations of 0.05, 0.075, 0.1 and 0.125 The non-specific binding of 3H-diazepam mm. was similarly measured but in the presence of 2 uM unlabeled diazepam. The value of the Results specific binding was calculated by sub 1. Displacement of 3H-diazepam binding: tracting the non-specific binding from the As shown in Fig. 2, the specific binding of total binding. The non-specific binding was 3H-diazepam was inhibited by 25% , 75% 5-10% of the specific binding. and almost completely by 0.01 i M, 0.1 u M Drugs tested were CM6912 and its and 1 W of CM6912, respectively. The metabolites CM6913 and CM7116. Di concentration of CM6912 to achieve 50% azepam, nitrazepam and lorazepam were also inhibition (IC50) was 25 nM. Both CM6913 used as reference compounds. These drugs and CM7116 at 0.01 aM also inhibited the were dissolved in dimethylsulfoxide (DM 3H-diazepam binding by about 80% , but S0). The final concentration of DMSO was CM7116 appeared to be more potent than 0.4%, and the specific binding of 3H CM6916 at all concentrations tested. At Fig. 2. Inhibition of the specific binding of 3H Fig. 3. Log dose-response curves for the sup diazepam by CM6912, CM6913 and CM7116. pressive action of GABA on the frequency of spon Cerebral cortical membrane suspension from rats was taneous spikes of cerebellar Purkinje cells and the incubated with various concentrations of one of potentiating effect of diazepam (5 iM and 10 M). benzodiazepines and 1.6 nM of 3H-diazepam for Abscissa: Concentrations of GABA on a loge scale. 30 min at 4°C. The values shown are the means of Ordinate: the maximum precentage inhibition of the three observations, S.D. being less than 1.5% of the spike frequency. The values plotted are the means mean. Abscissa: Concentrations (M) of CM691 2, +S.E.M. of 24 observations for the control and 8-9 CM6913 or CM7116. Ordinate: Percentage displace for diazepam (see Table 1 ). The solid lines are ment of 3H-diazepam binding. theoretical curves based on a Michaelis-Menten type formula (12, 13) and show the best fit to the observed data. 0.1 /iM, both CM6913 and CM7116 exhib ited nearly complete inhibition. The values of IC50 were 3.2 nM for CM6913 and 1.4 in this study. nM for CM7116. Typical dose-response curves for the Although not shown in Fig. 2, the IC50 inhibitory action of GABA and the effect of values for the other benzodiazepines diazepam are shown in Fig. 3. The control measured in a similar manner were 10 nM dose-response curve was clearly shifted to for diazepam, 3.4 nM for nitrazepam and 1.4 the left by the presence of 5 ,uM or 10 PM nM for lorazepam. Therefore, the potency of diazepam, indicating that the suppressive CM691 2 to inhibit the 3H-diazepam binding action of GABA was potentiated by this was weaker than that of diazepam, while benzodiazepine. CM6913 was as potent as nitrazepam, and As shown in Fig. 4, CM6912 or CM7116 CM7116 was comparable with lorazepam. also shifted the control curve to the left in a 2. Suppressive action of GABA on spon dose-dependent manner and in parallel. No taneous spike discharges of cerebellar antagonism was observed at all. Purkinje cells and the potentiating effect The values of percentage inhibition for thereon of CM6912, CM7116 and diazepam: GABA in the absence and presence of Spontaneous spike discharges of Purkinje diazepam, CM6912 or CM7116 are shown in cells are known to be rapidly and reversibly Table 1. Concentrations of GABA to show suppressed by superfused GABA (12, 13). 50% inhibition (IC50) in the absence and Such a suppression is usually followed by a presence of each benzodiazepine are listed in partial recovery even in the presence of Table 2.
Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn Et Al
    US 2004O224012A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn et al. (43) Pub. Date: Nov. 11, 2004 (54) TOPICAL APPLICATION AND METHODS Related U.S. Application Data FOR ADMINISTRATION OF ACTIVE AGENTS USING LIPOSOME MACRO-BEADS (63) Continuation-in-part of application No. 10/264,205, filed on Oct. 3, 2002. (76) Inventors: Pichit Suvanprakorn, Bangkok (TH); (60) Provisional application No. 60/327,643, filed on Oct. Tanusin Ploysangam, Bangkok (TH); 5, 2001. Lerson Tanasugarn, Bangkok (TH); Suwalee Chandrkrachang, Bangkok Publication Classification (TH); Nardo Zaias, Miami Beach, FL (US) (51) Int. CI.7. A61K 9/127; A61K 9/14 (52) U.S. Cl. ............................................ 424/450; 424/489 Correspondence Address: (57) ABSTRACT Eric G. Masamori 6520 Ridgewood Drive A topical application and methods for administration of Castro Valley, CA 94.552 (US) active agents encapsulated within non-permeable macro beads to enable a wider range of delivery vehicles, to provide longer product shelf-life, to allow multiple active (21) Appl. No.: 10/864,149 agents within the composition, to allow the controlled use of the active agents, to provide protected and designable release features and to provide visual inspection for damage (22) Filed: Jun. 9, 2004 and inconsistency. US 2004/0224012 A1 Nov. 11, 2004 TOPCAL APPLICATION AND METHODS FOR 0006 Various limitations on the shelf-life and use of ADMINISTRATION OF ACTIVE AGENTS USING liposome compounds exist due to the relatively fragile LPOSOME MACRO-BEADS nature of liposomes. Major problems encountered during liposome drug Storage in vesicular Suspension are the chemi CROSS REFERENCE TO OTHER cal alterations of the lipoSome compounds, Such as phos APPLICATIONS pholipids, cholesterols, ceramides, leading to potentially toxic degradation of the products, leakage of the drug from 0001) This application claims the benefit of U.S.
    [Show full text]
  • Understanding Benzodiazephine Use, Abuse, and Detection
    Siemens Healthcare Diagnostics, the leading clinical diagnostics company, is committed to providing clinicians with the vital information they need for the accurate diagnosis, treatment and monitoring of patients. Our comprehensive portfolio of performance-driven systems, unmatched menu offering and IT solutions, in conjunction with highly responsive service, is designed to streamline workflow, enhance operational efficiency and support improved patient care. Syva, EMIT, EMIT II, EMIT d.a.u., and all associated marks are trademarks of General Siemens Healthcare Diagnostics Inc. All Drugs other trademarks and brands are the Global Division property of their respective owners. of Abuse Siemens Healthcare Product availability may vary from Diagnostics Inc. country to country and is subject 1717 Deerfield Road to varying regulatory requirements. Deerfield, IL 60015-0778 Please contact your local USA representative for availability. www.siemens.com/diagnostics Siemens Global Headquarters Global Siemens Healthcare Headquarters Siemens AG Understanding Wittelsbacherplatz 2 Siemens AG 80333 Muenchen Healthcare Sector Germany Henkestrasse 127 Benzodiazephine Use, 91052 Erlangen Germany Abuse, and Detection Telephone: +49 9131 84 - 0 www.siemens.com/healthcare www.usa.siemens.com/diagnostics Answers for life. Order No. A91DX-0701526-UC1-4A00 | Printed in USA | © 2009 Siemens Healthcare Diagnostics Inc. Syva has been R1 R2 a leading developer N and manufacturer of AB R3 X N drugs-of-abuse tests R4 for more than 30 years. R2 C Now part of Siemens Healthcare ® Diagnostics, Syva boasts a long and Benzodiazepines have as their basic chemical structure successful track record in drugs-of-abuse a benzene ring fused to a seven-membered diazepine ring. testing, and leads the industry in the All important benzodiazepines contain a 5-aryl substituent ring (ring C) and a 1,4–diazepine ring.
    [Show full text]
  • Table 6.12: Deaths from Poisoning, by Sex and Cause, Scotland, 2016
    Table 6.12: Deaths from poisoning, by sex and cause, Scotland, 2016 ICD code(s), cause of death and substance(s) 1 Both Males Females ALL DEATHS FROM POISONING 2 1130 766 364 ACCIDENTS 850 607 243 X40 - X49 Accidental poisoning by and exposure to … X40 - Nonopioid analgesics, antipyretics and antirheumatics Paracetamol 2 1 1 Paracetamol, Cocaine, Amphetamine || 1 0 1 X41 - Antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not elsewhere classified Alprazolam, MDMA, Cocaine || Cannabis, Alcohol 1 1 0 Alprazolam, Methadone || Pregabalin, Tramadol, Gabapentin, Cannabis 1 1 0 Alprazolam, Morphine, Heroin, Dihydrocodeine, Buprenorphine || Alcohol 1 1 0 Alprazolam, Oxycodone, Alcohol || Paracetamol 1 0 1 Amitriptyline, Cocaine, Etizolam || Paracetamol, Codeine, Hydrocodone, Alcohol 1 1 0 Amitriptyline, Dihydrocodeine || Diazepam, Paracetamol, Verapamil, Alcohol 1 1 0 Amitriptyline, Fluoxetine, Alcohol 1 0 1 Amitriptyline, Methadone, Diazepam || 1 1 0 Amitriptyline, Methadone, Morphine, Etizolam || Gabapentin, Cannabis, Alcohol 1 1 0 Amitriptyline, Venlafaxine 1 0 1 Amphetamine 1 1 0 Amphetamine || 1 1 0 Amphetamine || Alcohol 1 1 0 Amphetamine || Chlorpromazine 1 1 0 Amphetamine || Fluoxetine 1 1 0 Amphetamine, Dihydrocodeine, Alcohol || Procyclidine, Tramadol, Duloxetine, Haloperidol 1 0 1 Amphetamine, MDMA || Diclazepam, Cannabis, Alcohol 1 1 0 Amphetamine, Methadone || 1 1 0 Amphetamine, Oxycodone, Gabapentin, Zopiclone, Diazepam || Paracetamol, Alcohol 1 0 1 Amphetamine, Tramadol || Mirtazapine, Alcohol 1 1 0 Benzodiazepine
    [Show full text]
  • Drug Names That Are Too Close for Comfort
    MEDICATION SAFETY Drug Names That Are Too Close for Comfort and therefore at risk of “seeing” prescriptions for the newer product clobazam as the more familiar clonazePAM. Use TWO IDENtifieRS at THE POS Within the span of a couple of days, the Institute for Safe Medication Practices received two more reports of wrong patient errors at the point-of-sale. Both were submitted by the parents of the patients involved. In one event, a teenager, who Look- and sound-alike similarity between the official names was supposed to receive methylphenidate for Attention Deficit clobazam (ONFI) and clonazePAM (KLONOPIN) has led Hyperactivity Disorder (ADHD), was given a cardiac drug to several reports expressing concern that patients may in- intended for a different patient. The mother who was picking advertently receive the wrong medication in either hospital up the prescription for her son caught the error because or outpatient settings. The drugs share similar indications, the pharmacist mentioned that “this will help with the chest although they have 10-fold strength difference in available pains.” Of course, this means that the other patient was given dosage forms. Clobazam was approved by Food and Drug the methylphenidate instead of the cardiac drug. It turned out Administration in October 2011 for adjunctive treatment of that the teenager and the other patient had the same name. Lennox-Gaustaut seizures and other epileptic syndromes. Lennox-Gaustaut is a form of childhood-onset epilepsy In the second case, a patient was dispensed amLODIPine, a characterized by frequent seizures and different seizure calcium channel blocker, instead of the anticonvulsant gab- types, often accompanied by developmental delay and apentin.
    [Show full text]
  • S1 Table. List of Medications Analyzed in Present Study Drug
    S1 Table. List of medications analyzed in present study Drug class Drugs Propofol, ketamine, etomidate, Barbiturate (1) (thiopental) Benzodiazepines (28) (midazolam, lorazepam, clonazepam, diazepam, chlordiazepoxide, oxazepam, potassium Sedatives clorazepate, bromazepam, clobazam, alprazolam, pinazepam, (32 drugs) nordazepam, fludiazepam, ethyl loflazepate, etizolam, clotiazepam, tofisopam, flurazepam, flunitrazepam, estazolam, triazolam, lormetazepam, temazepam, brotizolam, quazepam, loprazolam, zopiclone, zolpidem) Fentanyl, alfentanil, sufentanil, remifentanil, morphine, Opioid analgesics hydromorphone, nicomorphine, oxycodone, tramadol, (10 drugs) pethidine Acetaminophen, Non-steroidal anti-inflammatory drugs (36) (celecoxib, polmacoxib, etoricoxib, nimesulide, aceclofenac, acemetacin, amfenac, cinnoxicam, dexibuprofen, diclofenac, emorfazone, Non-opioid analgesics etodolac, fenoprofen, flufenamic acid, flurbiprofen, ibuprofen, (44 drugs) ketoprofen, ketorolac, lornoxicam, loxoprofen, mefenamiate, meloxicam, nabumetone, naproxen, oxaprozin, piroxicam, pranoprofen, proglumetacin, sulindac, talniflumate, tenoxicam, tiaprofenic acid, zaltoprofen, morniflumate, pelubiprofen, indomethacin), Anticonvulsants (7) (gabapentin, pregabalin, lamotrigine, levetiracetam, carbamazepine, valproic acid, lacosamide) Vecuronium, rocuronium bromide, cisatracurium, atracurium, Neuromuscular hexafluronium, pipecuronium bromide, doxacurium chloride, blocking agents fazadinium bromide, mivacurium chloride, (12 drugs) pancuronium, gallamine, succinylcholine
    [Show full text]
  • Pharmacological Management of Epilepsy
    Epilepsy management ❚ Review Pharmacological management of epilepsy Carole Brown MSc Clin Pharm, MPS, PIP, PwSI epilepsy There have been significant advances in the management of epilepsy since the appearance of bromide in 1857. In the last decade, many new drugs have been developed and general understanding of the condition has improved. Here, Pharmacist Epilepsy Practitioner, Carole Brown, considers the current choice of antiepileptic drugs (AEDs), mode of action, newer AEDS, when to start treatment, epilepsy guidelines, adverse effects of AEDs, generic substitution, therapeutic drug monitoring, driving, contraception and bone health. ong-term antiepileptic drugs (AEDs) remain the main- AEDs exert their effects in a number of ways: Lstay of epilepsy treatment. AEDs eliminate or reduce 1. Modulation of intrinsic membrane conduct- seizure frequency in up to 60–70% of patients.1 Treat- ance, to inhibit excessive firing of neurones, the ment for chronic diseases such as epilepsy means that main targets being sodium and calcium channels, patients often have complex medication regimens to exerting their therapeutic effect by preferential incorporate into their daily routines. AED choice should binding to the inactivated state of the sodium be tailored to individual patient factors that may limit channel, eg phenytoin, lamotrigine and carbamaz- medication use such as tolerability, treatment adherence epine. Kinetics vary, so carbamazepine binds less and side-effect profile. Non-adherence rates among potently but faster than phenytoin. The drugs pre- patients with epilepsy range from 30–50%.2 Clinicians vent the sustained repetitive firing of neurones so treating epilepsy patients note that non-adherent patients prolong the refractory period. Presynaptic pro- report more difficulty in attaining seizure control than teins modulate release of neurotransmitters patients adherent with their medication.
    [Show full text]
  • Calculating Equivalent Doses of Oral Benzodiazepines
    Calculating equivalent doses of oral benzodiazepines Background Benzodiazepines are the most commonly used anxiolytics and hypnotics (1). There are major differences in potency between different benzodiazepines and this difference in potency is important when switching from one benzodiazepine to another (2). Benzodiazepines also differ markedly in the speed in which they are metabolised and eliminated. With repeated daily dosing accumulation occurs and high concentrations can build up in the body (mainly in fatty tissues) (2). The degree of sedation that they induce also varies, making it difficult to determine exact equivalents (3). Answer Advice on benzodiazepine conversion NB: Before using Table 1, read the notes below and the Limitations statement at the end of this document. Switching benzodiazepines may be advantageous for a variety of reasons, e.g. to a drug with a different half-life pre-discontinuation (4) or in the event of non-availability of a specific benzodiazepine. With relatively short-acting benzodiazepines such as alprazolam and lorazepam, it is not possible to achieve a smooth decline in blood and tissue concentrations during benzodiazepine withdrawal. These drugs are eliminated fairly rapidly with the result that concentrations fluctuate with peaks and troughs between each dose. It is necessary to take the tablets several times a day and many people experience a "mini-withdrawal", sometimes a craving, between each dose. For people withdrawing from these potent, short-acting drugs it has been advised that they switch to an equivalent dose of a benzodiazepine with a long half life such as diazepam (5). Diazepam is available as 2mg tablets which can be halved to give 1mg doses.
    [Show full text]
  • Deconstructing Tolerance with Clobazam Post Hoc Analyses from an Open-Label Extension Study
    Deconstructing tolerance with clobazam Post hoc analyses from an open-label extension study Barry E. Gidal, PharmD ABSTRACT Robert T. Wechsler, MD, Objective: To evaluate potential development of tolerance to adjunctive clobazam in patients with PhD Lennox-Gastaut syndrome. Raman Sankar, MD, PhD Methods: Eligible patients enrolled in open-label extension study OV-1004, which continued until Georgia D. Montouris, clobazam was commercially available in the United States or for a maximum of 2 years outside MD the United States. Enrolled patients started at 0.5 mg$kg21$d21 clobazam, not to exceed H. Steve White, PhD 40 mg/d. After 48 hours, dosages could be adjusted up to 2.0 mg$kg21$d21 (maximum 80 mg/d) James C. Cloyd, PharmD on the basis of efficacy and tolerability. Post hoc analyses evaluated mean dosages and drop- Mary Clare Kane, PhD seizure rates for the first 2 years of the open-label extension based on responder categories and Guangbin Peng, MS baseline seizure quartiles in OV-1012. Individual patient listings were reviewed for dosage David M. Tworek, MS, increases $40% and increasing seizure rates. MBA Vivienne Shen, MD, PhD Results: Data from 200 patients were included. For patients free of drop seizures, there was no Jouko Isojarvi, MD, PhD notable change in dosage over 24 months. For responder groups still exhibiting drop seizures, dosages were increased. Weekly drop-seizure rates for 100% and $75% responders demon- strated a consistent response over time. Few patients had a dosage increase $40% associated Correspondence to with an increase in seizure rates. Dr. Gidal: [email protected] Conclusions: Two-year findings suggest that the majority of patients do not develop tolerance to the antiseizure actions of clobazam.
    [Show full text]
  • Drugs of Abuse: Benzodiazepines
    Drugs of Abuse: Benzodiazepines What are Benzodiazepines? Benzodiazepines are central nervous system depressants that produce sedation, induce sleep, relieve anxiety and muscle spasms, and prevent seizures. What is their origin? Benzodiazepines are only legally available through prescription. Many abusers maintain their drug supply by getting prescriptions from several doctors, forging prescriptions, or buying them illicitly. Alprazolam and diazepam are the two most frequently encountered benzodiazepines on the illicit market. Benzodiazepines are What are common street names? depressants legally available Common street names include Benzos and Downers. through prescription. Abuse is associated with What do they look like? adolescents and young The most common benzodiazepines are the prescription drugs ® ® ® ® ® adults who take the drug Valium , Xanax , Halcion , Ativan , and Klonopin . Tolerance can orally or crush it up and develop, although at variable rates and to different degrees. short it to get high. Shorter-acting benzodiazepines used to manage insomnia include estazolam (ProSom®), flurazepam (Dalmane®), temazepam (Restoril®), Benzodiazepines slow down and triazolam (Halcion®). Midazolam (Versed®), a short-acting the central nervous system. benzodiazepine, is utilized for sedation, anxiety, and amnesia in critical Overdose effects include care settings and prior to anesthesia. It is available in the United States shallow respiration, clammy as an injectable preparation and as a syrup (primarily for pediatric skin, dilated pupils, weak patients). and rapid pulse, coma, and possible death. Benzodiazepines with a longer duration of action are utilized to treat insomnia in patients with daytime anxiety. These benzodiazepines include alprazolam (Xanax®), chlordiazepoxide (Librium®), clorazepate (Tranxene®), diazepam (Valium®), halazepam (Paxipam®), lorzepam (Ativan®), oxazepam (Serax®), prazepam (Centrax®), and quazepam (Doral®).
    [Show full text]
  • Introduced B.,Byhansen, 16
    LB301 LB301 2021 2021 LEGISLATURE OF NEBRASKA ONE HUNDRED SEVENTH LEGISLATURE FIRST SESSION LEGISLATIVE BILL 301 Introduced by Hansen, B., 16. Read first time January 12, 2021 Committee: Judiciary 1 A BILL FOR AN ACT relating to the Uniform Controlled Substances Act; to 2 amend sections 28-401, 28-405, and 28-416, Revised Statutes 3 Cumulative Supplement, 2020; to redefine terms; to change drug 4 schedules and adopt federal drug provisions; to change a penalty 5 provision; and to repeal the original sections. 6 Be it enacted by the people of the State of Nebraska, -1- LB301 LB301 2021 2021 1 Section 1. Section 28-401, Revised Statutes Cumulative Supplement, 2 2020, is amended to read: 3 28-401 As used in the Uniform Controlled Substances Act, unless the 4 context otherwise requires: 5 (1) Administer means to directly apply a controlled substance by 6 injection, inhalation, ingestion, or any other means to the body of a 7 patient or research subject; 8 (2) Agent means an authorized person who acts on behalf of or at the 9 direction of another person but does not include a common or contract 10 carrier, public warehouse keeper, or employee of a carrier or warehouse 11 keeper; 12 (3) Administration means the Drug Enforcement Administration of the 13 United States Department of Justice; 14 (4) Controlled substance means a drug, biological, substance, or 15 immediate precursor in Schedules I through V of section 28-405. 16 Controlled substance does not include distilled spirits, wine, malt 17 beverages, tobacco, hemp, or any nonnarcotic substance if such substance 18 may, under the Federal Food, Drug, and Cosmetic Act, 21 U.S.C.
    [Show full text]
  • The Emergence of New Psychoactive Substance (NPS) Benzodiazepines
    Issue: Ir Med J; Vol 112; No. 7; P970 The Emergence of New Psychoactive Substance (NPS) Benzodiazepines. A Survey of their Prevalence in Opioid Substitution Patients using LC-MS S. Mc Namara, S. Stokes, J. Nolan HSE National Drug Treatment Centre Abstract Benzodiazepines have a wide range of clinical uses being among the most commonly prescribed medicines globally. The EU Early Warning System on new psychoactive substances (NPS) has over recent years detected new illicit benzodiazepines in Europe’s drug market1. Additional reference standards were obtained and a multi-residue LC- MS method was developed to test for 31 benzodiazepines or metabolites in urine including some new benzodiazepines which have been classified as New Psychoactive Substances (NPS) which comprise a range of substances, including synthetic cannabinoids, opioids, cathinones and benzodiazepines not covered by international drug controls. 200 urine samples from patients attending the HSE National Drug Treatment Centre (NDTC) who are monitored on a regular basis for drug and alcohol use and which tested positive for benzodiazepine class drugs by immunoassay screening were subjected to confirmatory analysis to determine what Benzodiazepine drugs were present and to see if etizolam or other new benzodiazepines are being used in the addiction population currently. Benzodiazepine prescription and use is common in the addiction population. Of significance we found evidence of consumption of an illicit new psychoactive benzodiazepine, Etizolam. Introduction Benzodiazepines are useful in the short-term treatment of anxiety and insomnia, and in managing alcohol withdrawal. 1 According to the EMCDDA report on the misuse of benzodiazepines among high-risk opioid users in Europe1, benzodiazepines, especially when injected, can prolong the intensity and duration of opioid effects.
    [Show full text]
  • Pharmaceuticals As Environmental Contaminants
    PharmaceuticalsPharmaceuticals asas EnvironmentalEnvironmental Contaminants:Contaminants: anan OverviewOverview ofof thethe ScienceScience Christian G. Daughton, Ph.D. Chief, Environmental Chemistry Branch Environmental Sciences Division National Exposure Research Laboratory Office of Research and Development Environmental Protection Agency Las Vegas, Nevada 89119 [email protected] Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Why and how do drugs contaminate the environment? What might it all mean? How do we prevent it? Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada This talk presents only a cursory overview of some of the many science issues surrounding the topic of pharmaceuticals as environmental contaminants Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada A Clarification We sometimes loosely (but incorrectly) refer to drugs, medicines, medications, or pharmaceuticals as being the substances that contaminant the environment. The actual environmental contaminants, however, are the active pharmaceutical ingredients – APIs. These terms are all often used interchangeably Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Office of Research and Development Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdfNational
    [Show full text]